ACR 2020 - RA Highlights Brochure

Enhancing knowledge of the clinical
importance of cytokine signalling
The Cytokine Signalling Forum
www.cytokinesignalling.com
ACR 2020
Congress Highlights
Rheumatoid Arthritis
Developed under
the auspices of the
University of Glasgow
Register for all this FREE content at
www.cytokinesignalling.com

Chairman’s Introduction
Dear CSF Member,
Welcome to this year’s selection of ACR abstracts on cytokine signalling agents marketed for use in RA and my
‘Chairman’s Picks’. Every year the number of data concerning these agents continues to grow, and so, for this year’s
ACR we have focussed our selections herein only on RA - other indications are addressed in a separate review.
The largest number of abstracts this year concerns upadacitinib. Key among them are the 72-week monotherapy
MTX-naïve data [0207], and 84-week monotherapy data with prior inadequate response to MTX [0209]. Sustainability
of response to upadacitinib vs adalimumab will be presented [0214], along with the long-term safety and effectiveness
at 72-weeks of the same study [0212]. The incidence and risk of VTEs in RA patients treated with upadacitinib is
also described [0215]. There is an interesting analyses of the response to pneumococcal vaccination in RA patients
from an open-label phase 2 extension study [1996] and the incidence and risk factors for HZ in RA patients receiving
upadacitinib from the phase 3 programme [2002]. In addition, Bergman M et al. examine PROs of upadacitinib vs
abatacept from the SELECT-CHOICE study [1728].
Filgotinib is the therapeutic subject of several interesting abstracts, with a post-hoc analysis of work productivity [0141],
52-week efficacy and safety results [0208] from the FINCH-1 trial and efficacy and safety results in MTX-naïve RA
patients [0217]. Additional analyses of the phase 3 filgotinib programme include an examination of the effect of filgotinib
on pain [1201] and SF-36 and HAQ-DI [0136] across both studies, plus an in depth looks at pain relief, fatigue and
QoL in patients with inadequate response to bDMARDs [1215], and naïve to methotrexate [1216].
There are also a number of interesting abstracts presented on tofacitinib and baricitinib. For tofacitinib there is a
study on the comparative effectiveness of tofacitinib vs abatacept in ACPA+ patients [0824] and an examination of
tofacitinib’s impact on weight [1203]. In real world studies, there is an abstract from Madariaga H et al. presenting
the impact of tofacitinib vs bDMARDs on PROs in two Latin American countries [1241] - there are also results from
a cohort study on time to discontinuation of tofacitinib and TNF inhibitors with or without MTX [0808]. We will also
see effects on bone metabolism following one-year tofacitinib treatment in RA [0104]. Turning to baricitinib, Winthrop K
et al. present an updated integrated safety analysis up to 8.4 years [0202] and van der Heijde et al. present on 5-year
radiographic progression data. There is also an analyses of PROs from the RA-BEACON and RA-BUILD trials [1228].
Within the following pages, we share our detailed selection of the congress highlights. As always, thank you for your
continued support, and we hope you enjoy the virtual ACR 2020 experience. Of course, the most important message
is to wish you safe times for you and your families!
Kind regards,
Prof. Iain McInnes
Chairman’s picks

Key Presentations
Friday, November 6, 2020
POSTER SESSION A • 09:00 – 11:00
Osteoporosis & Metabolic Bone Disease
0104 Bone Effects of One-year Tofacitinib Treatment in
Rheumatoid Arthritis
Patient Outcomes, Preferences, & Attitudes
Poster I: RA, Spondyloarthritis, & OA
0136 Filgotinib Significantly Improved Patient-reported
Health-related Quality of Life for Patients with
Active Rheumatoid Arthritis: A Post Hoc Analysis of
SF-36 and HAQ-DI from Phase 3 Studies
0141 Filgotinib Improved Work Productivity and Activity
Impairment in Patients with Rheumatoid Arthritis
and Inadequate Response to Methotrexate:
Results from FINCH-1 Study
RA – Treatments Poster I: RA Treatments &
Their Safety
0200 Predictors of Durable Clinical Response to
Tofacitinib 11 Mg Once Daily with or Without
Methotrexate in Patients with Rheumatoid Arthritis:
Post Hoc Analysis of Data from a Phase 3b/4
Methotrexate Withdrawal Study
0202 Safety Profile of Baricitinib for the Treatment of
Rheumatoid Arthritis up to 8.4 Years: An Updated
Integrated Safety Analysis
0203 Safety of Baricitinib in Patients with Rheumatoid
Arthritis: Interim Report from All-Case
Post‐Marketing Study in Clinical Use
0207 Upadacitinib Monotherapy in Methotrexate-naïve
Patients with Rheumatoid Arthritis: Results at
72 Weeks
0208 Efficacy and Safety of Filgotinib for Patients with
Rheumatoid Arthritis with Inadequate Response to
Methotrexate: 52-Week Results
0209 Upadacitinib as Monotherapy in Patients with
Rheumatoid Arthritis and Prior Inadequate
Response to Methotrexate: Results at 84 Weeks
0212 Long-Term Safety and Effectiveness of Upadacitinib
or Adalimumab in Patients with Rheumatoid
Arthritis: Results at 72 Weeks
0213 Sustainability of Response to Upadacitinib as
Monotherapy or in Combination Among Patients
with Rheumatoid Arthritis and Prior Inadequate
Response to Conventional Synthetic DMARDs
0214 Sustainability of Response Between Upadacitinib
and Adalimumab Among Patients with
Rheumatoid Arthritis and Prior Inadequate
Response to Methotrexate
0215 Incidence and Risk of Venous Thromboembolic
Events Among Patients with Rheumatoid Arthritis
Enrolled in the Upadacitinib Clinical Trial Program
0216 A Subgroup Analysis of Low Disease Activity
and Remission from Phase 3 Study of Filgotinib
in Patients with Inadequate Response to
Biologic DMARDs
0217 Efficacy and Safety of Filgotinib in
Methotrexate-Naïve Patients with Rheumatoid
Arthritis: 52-Week Results
0222 tsDMARD Therapy Is Associated with More Initial
Therapy Prolongations Compared to bDMARDs
Both in Bionaive and Bioexperienced Patients with
Rheumatoid Arthritis
0224 Efficacy of Long-term Treatment with Baricitinib
2 Mg in Patients with Active Rheumatoid Arthritis
0227 Real Life Severe Infections in Patients with
Rheumatoid Arthritis on Treatment with Biological
Therapy and JAK Inhibitors
Chairman’s picks

0228 Impact of Upadacitinib or Adalimumab as Initial
Therapy on the Achievement of 48-Week
Treatment Goals in Patients with Rheumatoid
Arthritis and Inadequate Response to Methotrexate:
Post Hoc Analysis of a Phase 3 Study
0229 Integrated Safety of Filgotinib in Patients with
Moderately or Severely Active Rheumatoid Arthritis
Receiving Treatment for up to 5.5 Years
0234 Characterization of Serious Infections with
Upadacitinib in Patients with Rheumatoid Arthritis
0237 Safety Profile of Upadacitinib up to 3 Years of
Exposure in Patients with Rheumatoid Arthritis
0239 Adjudicated MACE and VTE in the Filgotinib RA
Program: Integrated Analysis from Phase 2 and 3
Clinical Trial
ABSTRACT SESSION • 15:00 – 15:50
Immunological Complications of Therapy
0453 Monitoring of BK Reactivation and Long-term
Safety on JAK1/2 Inhibition with Baricitinib
Saturday, November 7, 2020
POSTER SESSION B • 09:00 – 11:00
RA – Treatments Poster II: Comparative
Effectiveness, Biosimilars, Adherence &
the Real World
0808 Time to Discontinuation of Tofacitinib and TNF
Inhibitors in Rheumatoid Arthritis Patients with and
Without Methotrexate: Real World Results from a
Rheumatoid Arthritis Cohort
0813 Treatment Outcomes in Patients with Seropositive
versus Seronegative Rheumatoid Arthritis in Czech
Registry ATTRA Treated with JAK Inhibitors
0818 Efficacy and Safety of Switching Jakinibs in
Rheumatoid Arthritis
0824 The Comparative Effectiveness of Abatacept versus
Tofacitinib After 6 Months of Treatment in Patients
with RA Who Were Anti-citrullinated Protein
Antibody Positive at Baseline: Results from a US
National Observational Study
0825 Sex Differences in the Efficacy and Safety of
Tofacitinib in Rheumatoid Arthritis Patients:
A Post Hoc Analysis of Phase 3 and Long-Term
Extension Trials
0827 Comparative Clinical Efficacy of Sarilumab versus
Upadacitinib over 12 Weeks: Matching-Adjusted
Indirect Comparison Analysis
0828 Clinical and Functional Response to Tofacitinib in
Patients with Rheumatoid Arthritis: Probability Plot
Analysis of Results from a Phase 3b/4 Methotrexate
Withdrawal Study
0830 Discontinuation Rate of Tofacitinib Is Similar When
Compared to TNF Inhibitors in Rheumatoid Arthritis
Patients: Real World Results from a Rheumatoid
Arthritis Cohort
Chairman’s picks

Sunday, November 8, 2020
POSTER SESSION C • 09:00 – 11:00
Epidemiology & Public Health Poster III:
Inflammatory Rheumatic Disease
1005 Risk of Non-vertebral Fractures Among
Rheumatoid Arthritis Patients Treated with Biologic
or Targeted-Synthetic DMARDs: A Multi-Database
Comparative Safety Study
1011 Effectiveness, Safety and Quality of Life with
Tofacitinib Treatment in Adult Patients with
Rheumatoid Arthritis Under Routine Clinical Care:
First Interim Results from a German Non-Interventional,
Prospective, Multi-Center Study
RA – Treatments Poster III: PROs, Biomarkers,
Systemic Inflammation & Radiographs
1201 Effect of Filgotinib on Pain in Patients with
Rheumatoid Arthritis: Results from Phase 3
Clinical Trials
1203 Analysis of the Impact of Tofacitinib Treatment on
Weight in Patients with Rheumatoid Arthritis
1211 Relationship Between Changes in Lipid Levels
and Improvement in Disease Activity Outcomes
in Patients with Rheumatoid Arthritis Receiving
Upadacitinib Treatment: Pooled Analysis of Data
from Two Phase 3 Studies
1212 Whole Blood Transcriptional Changes Following
Selective Inhibition of Janus Kinase 1 (JAK1) by
Filgotinib in MTX-Naïve Adults with Moderately-to-
Severely Active Rheumatoid Arthritis (RA)
1215 Filgotinib Provided Rapid and Sustained Relief of
Pain and Fatigue and Improved Health-Related
Quality of Life in Patients with Rheumatoid Arthritis
and Inadequate Response to Biologic DMARDs
1216 Filgotinib Provided Rapid and Sustained
Improvements in Functional Status, Pain, and
Health Related Quality of Life, and Reduced Fatigue
over Time in Patients with Rheumatoid Arthritis
Who Are Methotrexate-Naïve: Results from a
Phase 3 Study
1218 Filgotinib Provided Rapid and Sustained
Improvements in Functional Status, Pain,
Health-related Quality of Life, and Fatigue in
Patients with Rheumatoid Arthritis and Inadequate
Response to Methotrexate
1225 Targeting to IL-6 or Specific JAKs for RA Treatment:
Seeking a Rationale for Switching Each Other
If One of These Treatments Resulted in Lack
of Efficacy
1228 Baricitinib 2-mg Provides Greater Improvements
in Patient-Reported Outcomes Across All Disease
Activity Levels Compared to Placebo: Post-hoc
Analyses of RA-BEACON and RA-BUILD Trials
1231 Radiographic Outcomes in Patients with
Rheumatoid Arthritis Receiving Upadacitinib as
Monotherapy or in Combination with Methotrexate:
Results at 2 Years
1235 Radiographic Progression of Structural Joint
Damage over 5 Years of Baricitinib Treatment in
Patients with Rheumatoid Arthritis: Results from
RA-BEYOND
1239 Peripheral Protein Biomarker Changes Following
Selective Inhibition of Janus Kinase 1 (JAK1)
by Filgotinib in Methotrexate Naïve Adults with
Moderately-to-Severely Active Rheumatoid Arthritis
1241 Patient-Reported Outcomes in Rheumatoid Arthritis
Patients Treated with Tofacitinib or Biological
DMARDs in Real Life Conditions in Two Latin
America Countries
Chairman’s picks

Monday, November 9, 2020
POSTER SESSION D • 09:00 – 11:00
Imaging of Rheumatic Diseases Poster
1551 Rapid Effect of Tofacitinib in Reducing US Joint and
Tendon Inflammatory Lesions of RA Patients: Data
from a 24 Weeks Longitudinal Study
RA – Diagnosis, Manifestations, &
Outcomes Poster IV: Lifespan of a Disease
1728 Patient-Reported Outcomes of Upadacitinib versus
Abatacept in Patients with Rheumatoid Arthritis
and an Inadequate Response to Biologic
Disease-Modifying Antirheumatic Drugs:
12-Week Results of a Phase 3 Study
1749 Efficacy of Filgotinib in Patients with Rheumatoid
Arthritis with Poor Prognostic Factors:
Post Hoc Analysis
1752 Prediction of Responder and Non-responder to JAK
Inhibitors in Patients with Rheumatoid Arthritis:
A Pilot Study with Integrative Cluster Analysis
1763 Blending Hierarchical Cluster Analysis and
Cluster-Specific Regressions to Predict Clinical
Outcome to Tofacitinib Treatment in Patients with
Rheumatoid Arthritis
ABSTRACT SESSION • 10:00 – 10:50
RA – Treatments I: Maximizing Health in RA
1996 Evaluation of Response to Pneumococcal
Vaccination in Patients with Rheumatoid Arthritis
Receiving Upadacitinib: Results from a Phase 2
Open-Label Extension Study
1997 Immunogenicity of Adjuvanted Herpes Zoster
Subunit Vaccine in Rheumatoid Arthritis Patients
Treated with Janus Kinase Inhibitors and Controls:
Preliminary Results
ABSTRACT SESSION • 15:00 – 15:50
RA – Treatments II: Potential Harms &
Adverse Events
2002 Incidence and Risk Factors for Herpes Zoster
in Rheumatoid Arthritis Patients Receiving
Upadacitinib
Chairman’s picks

SPONSORSHIP AND UNRESTRICTED EDUCATIONAL GRANTS FROM
IN PARTNERSHIP WITH
Register for all this FREE content at
www.cytokinesignalling.com
www.cytokinesignalling.com
info@cytokinesignalling.com
Cytokine Signalling Forum
Cytokine Signalling Forum
@CytokineForum
Sponsorship and unrestricted educational grants from AbbVie, Pfizer, Gilead and Galapagos. | In partnership with Lilly
Developed under the auspices of the
University of Glasgow